© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).